Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma

Miyasaka, Mitsuru; Noji, Takehiro; Ohtaka, Kazuto; Chiba, Ryohei; Sato, Sunao; Shoji, Yasushi; Hase, Ryunosuke; Ichimura, Tsuyoshi; Hirano, Satoshi; Senmaru, Naoto

doi:10.1007/s12328-017-0781-9

Cited by 9 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patient who underwent pulmonary metastasectomy showed the longest median PRS and OS. In recent years, interest in this approach has increased, with numerable case reports [27][28][29][30][31][32][33] and several case series 17,34,35 published mostly from institutions in the United States and Japan. Similar to the current study, previous reports on pulmonary metastasectomy describe low rates of surgery-related morbidity and mortality, while median survival after metastasectomy of up to 47 months was observed.…”

Section: Discussionmentioning

confidence: 99%

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival

Groot

Blair

Gemenetzis

et al. 2019

HPB

View full text Add to dashboard Cite

Background: The literature suggests favorable survival for patients with isolated pulmonary recurrence after resection of pancreatic ductal adenocarcinoma (PDAC) as compared to other recurrence patterns. Within this cohort, it remains unclear what factors are associated with improved survival. Methods: Patients who developed pulmonary recurrence after pancreatectomy were selected from a prospective database. Predictors for post-recurrence survival (PRS) were analyzed using a multivariable Cox regression model. Results: Ninety-six patients were included. Median recurrence-free survival (RFS), PRS and overall survival (OS) were 16.3, 18.8 and 39.6 months, respectively. Further systemic treatment and/or metastasectomy (n = 64, 67%) was associated with significantly improved PRS and OS when compared to best supportive care (n = 35, 22%) (26.3 vs. 5.3 and 48.1 vs. 18.4, respectively; both P < 0.001). Patients who were able to undergo metastasectomy (n = 19) achieved a PRS and OS of 35.0 and 68.9 months, respectively. More than 5 pulmonary lesions, symptoms and CA 19-9 100 U/mL at time of recurrence were predictive of decreased PRS. A recurrence-free interval of >16 months and treatment for recurrence were independently associated with improved PRS. Conclusions: Isolated pulmonary recurrence occurs in 13% of patients with recurrent PDAC and is associated with a median OS of 40 months. Aggressive treatment in highly selected patients was correlated with improved survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival

Groot

Blair

Gemenetzis

et al. 2019

HPB

View full text Add to dashboard Cite

show abstract

“…Better survival rates have been found in patients treated with surgical resection of pulmonary metastases compared to those treated with metastasisdirected chemotherapy or observation 25,26 . Rare cases of solitary metastases of pancreatic cancer in the lungs can be cured with aggressive resection.…”

Section: Resultsmentioning

confidence: 99%

Current status of pancreatic cancer with oligometastasis

Chapa-Azuela,

Corona-Torres,

Ayala-Moreno

et al. 2024

CIRUE

View full text Add to dashboard Cite

Background. Pancreatic cancer is the seventh leading cause of death worldwide, with ductal adenocarcinoma as the most frequent neoplasm. Half of the patients who are diagnosed have metastases at the time of diagnosis. Objective. A review of the treatment of resectable pancreatic adenocarcinoma with oligometastatic disease was carried out in order to present an overview of the existing evidence. Method. A bibliographic search was carried in PubMed/Medline, Clinical Key and Index Medicus vhith MESH terms, from the year 1993 to 2022. Results. Patients with liver or lung metastases due to pancreatic ductal adenocarcinoma who undergo surgery and chemotherapy have a longer survival in carefully selected patients. Conclusions. The evidence regarding surgery in patients with pancreatic ductal adenocarcinoma and oligometastasis is limited and further randomized controlled trials are needed for both scenarios. As well as established criteria that help the selection of patients who can receive this type of treatment.

show abstract

“…Se han encontrado mejores tasas de sobrevida en los pacientes tratados mediante resección quirúrgica de metástasis pulmonares en comparación con los tratados con quimioterapia dirigida a metástasis u observación 25,26 . Los raros casos de metástasis solitarias de cáncer de páncreas en el pulmón pueden curarse con una resección agresiva, pero los criterios para la selección quirúrgica aún no están claros.…”

Section: Resultsunclassified

Estado actual del cáncer de páncreas con oligometástasis

Chapa-Azuela¹,

Corona-Torres²,

Ayala-Moreno³

et al. 2023

CIRU

View full text Add to dashboard Cite

Antecedentes. El cáncer pancreático es la séptima causa de muerte en el mundo, siendo el adenocarcinoma ductal del páncreas la neoplasia más frecuente. La mitad de los pacientes que son diagnosticados presentan metástasis al momento del diagnóstico. Objetivo. Se realizó una revisión sobre el tratamiento del adenocarcinoma pancreático resecable con enfermedad oligometastásica con el fin de presentar un panorama sobre la evidencia existente. Método. Se realizó una búsqueda bibliográfica en PubMed/Medline, Clinical Key e Index Medicus con términos MESH desde 1993 hasta 2022. Resultados. Los pacientes con metástasis hepáticas o pulmonares por adenocarcinoma ductal de páncreas que son sometidos a cirugía y quimioterapia tienen una mayor sobrevida en casos cuidadosamente seleccionados. Conclusiones. La evidencia respecto a la cirugía en pacientes con adenocarcinoma ductal de páncreas y oligometástasis es limitada y se necesitan ensayos controlados aleatorizados adicionales para ambos escenarios, así como criterios bien establecidos que ayuden a la selección de los pacientes que pueden recibir este tipo de tratamiento.

show abstract

Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma

Abstract: This patient has survived over the long term after undergoing three resections of lung metastases from resected pancreatic ductal adenocarcinoma.

Cited by 9 publications

References 32 publications

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival

Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival

Current status of pancreatic cancer with oligometastasis

Estado actual del cáncer de páncreas con oligometástasis

Contact Info

Product

Resources

About